Novo Nordisk Says CagriSema Analyses Show 25% Mean Weight Loss
Novo Nordisk said analyses from a Phase 3 study of its investigational CagriSema treatment showed 25% mean weight loss.
Novo Nordisk said analyses from a Phase 3 study of its investigational CagriSema treatment showed 25% mean weight loss.